An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Extension study for subjects currently participating in protocols ACH443-015 and ACH443-018.
Phase:
Phase 2
Details
Lead Sponsor:
Achillion Pharmaceuticals Alexion Pharmaceuticals
Collaborators:
Bellos, Nicholaos C., M.D. Center for the Prevention and Treatment of Infections Central Texas Primary Care Research Network Orlando Immunology Center Saint Michael